UPDATE 1-Gilead posts higher profit, strong hepatitis C drug sales
February 04, 2014 at 18:25 PM EST
Feb 4 (Reuters) - Gilead Sciences Inc, which recently began selling a new hepatitis C drug seen reaching multibillion-dollar sales, posted a better-than-expected quarterly profit on Tuesday as sales of its flagship HIV drugs beat Wall Street estimates.
